Omidubicel is an investigational therapy for patients with high-risk hematologic
malignancies.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04260698.
Locations matching your search criteria
United States
North Carolina
Durham
Duke University Medical CenterStatus: Active
Name Not Available
Successful blood and marrow transplantation (BMT) requires the infusion of a sufficient
number of hematopoietic stem/progenitor cells (HSPCs), capable of both homing to the bone
marrow and regenerating a full array of hematopoietic cell lineages with early and late
repopulating ability in a timely fashion.
Omidubicel is a stem/progenitor cell-based product composed of ex vivo expanded
allogeneic cells from one entire unit of umbilical cord blood. Omidubicel utilizes the
small molecule nicotinamide (NAM), as an epigenetic approach to inhibit differentiation
and to increase the migration, bone marrow (BM) homing and engraftment efficiency of
hematopoietic progenitor cells (HPC) expanded in ex vivo cultures.
The overall study objectives are to provide access to omidubicel for transplantation in
patients with hematological malignancies and to collect additional safety and efficacy
data.
Lead OrganizationGamida Cell